(TBPH) Theravance Biopharma, Inc. Business Model Canvas Research

Janssen Biotech is one of Theravance Biopharma, Inc.'s named collaboration partners, and these agreements help split development risk while giving access to Janssen's research and regulatory scale. That matters for immune and inflammatory assets, where late-stage trials can cost tens of millions of dollars and need deep biologic know-how.

• Shares cost and clinical risk
• Adds biologics expertise
• Supports immune pipeline progress

Theravance Biopharma, Inc. lists Alfasigma S.p.A. and Takeda Pharmaceutical Company Limited as collaboration partners, giving it 2 named strategic links in gastrointestinal and other specialty disease areas. These agreements help widen the Company’s reach across multiple therapeutic categories and support program expansion without relying on one partner.

• 2 named collaboration partners
• Gastrointestinal focus
• Broader specialty disease reach

Theravance Biopharma uses partnered commercialization support instead of a broad sales force, so it helps partners on market access, brand strategy, and lifecycle management for YUPELRI and TRELEGY. In 2025, that model let it focus on 2 key partnered assets while avoiding the cost of building a large commercial team.

• Supports partner launch execution
• Coordinates access and pricing work
• Guides brand and lifecycle choices
• Centers on YUPELRI and TRELEGY

Theravance Biopharma, Inc. actively manages licenses, collaborations, and intellectual property to turn partnered assets into cash without relying only on product sales. This model helps fund multiple development programs and keeps R&D aligned with the highest-value assets, with partnership-driven revenue still central to its 2025-2026 strategy.

• Monetizes assets beyond direct sales
• Uses licenses to fund R&D
• Keeps IP and partners tightly managed

Theravance Biopharma, Inc.’s scientific and clinical expertise covers discovery, translational research, and clinical development, and it is central to moving highly targeted inhaled, gut-selective, and oral compounds forward. This know-how is a key intangible asset because it de-risks programs before late-stage capital is committed.

• Drives target selection, trial design, and dose refinement.

Theravance Biopharma’s partner network is a core resource: Viatris, Pfizer, Janssen Biotech, Alfasigma, and Takeda extend development and commercialization reach without building every function in-house. This lowers cash burn pressure; in 2024, the Company reported $161.2 million in cash and cash equivalents and short-term investments, helping fund operations while partnerships scale value.

• Expands market access
• Shares development risk
• Reduces internal funding needs

Partnered access lets Theravance Biopharma, Inc. reach large respiratory markets through partners, so it does not need to build a full global sales force. That lowers execution risk and supports scale for brands like YUPELRI, while the partnered COPD market itself is huge, with about 390 million people living with COPD worldwide.

• Uses partner field teams

• Lowers global launch cost

• Scales with less risk

Theravance Biopharma’s pipeline spans 5 mechanisms: LAMA, JAK, NRI, ALK5, and 5-HT4. That mix lowers single-asset risk and gives the Company more than 1 path to value creation, which is a strong fit for specialty care.

• 5 mechanisms broaden success odds
• Less reliance on 1 program
• Supports a specialty-care story

In Business Model Canvas terms, this diversity strengthens the value proposition by pairing respiratory, immunology, and other niche settings into one pipeline story.

Theravance Biopharma, Inc. has 1 approved U.S. product, YUPELRI, so pharmacovigilance and adverse-event reporting stay central to customer relationships. Ongoing safety follow-up helps keep clinicians, patients, and regulators confident, and it protects the brand’s long-term value.

• 1 approved product needs close monitoring
• Safety reports support regulator trust
• Follow-up helps protect brand durability

Theravance Biopharma, Inc. relies on hospitals, trial sites, and investigators to enroll patients fast and collect clean data across its clinical programs. These relationships sit at the core of pipeline execution, because site quality drives speed, retention, and data integrity in each study.

• Site trust supports enrollment.
• Investigators improve data quality.
• Hospitals enable pipeline progress.

Theravance Biopharma, Inc. uses hospitals and research centers as the main channel for pipeline execution, including Phase 3 work that depends on patient enrollment and clinical data capture. These sites gate late-stage development, so delays in site activation or recruitment can push timelines and raise trial cost.

• Hospitals recruit and treat patients
• Research centers generate trial data
• Late-stage work stops without sites

Theravance Biopharma, Inc. uses digital medical information and corporate web content to build awareness for investigators, clinicians, and investors, and it supports direct field engagement. This channel helps share trial updates, pipeline news, and financial disclosures quickly; in FY2025, the company’s online IR and medical pages were key touchpoints for stakeholders.

• Web content supports trial awareness
• IR pages reach investors fast
• Complements direct relationship sales

Theravance Biopharma, Inc. targets neurologists and autonomic disorder specialists because ampreloxetine is in development for neurogenic orthostatic hypotension, a niche often tied to Parkinson’s disease and related autonomic failure. The US Parkinson’s population is about 1 million, and nOH affects a meaningful subset, so this segment is small but clinically important.

• Core prescribers for nOH care
• High-fit niche for ampreloxetine
• Linked to Parkinson’s and autonomic failure

Hospitals matter because severe lung injury and acute-care cases often start there, and the U.S. has about 6,100 hospitals that can drive early use in ICU and inpatient settings. Payers and pharmacy benefit managers shape access to branded respiratory drugs, with the three largest PBMs managing about 80% of U.S. prescriptions, so they strongly affect reimbursement, adoption, and patient reach.

• Hospitals influence acute-care uptake.
• PBMs decide formulary access.
• Payers control reimbursement speed.

Theravance Biopharma, Inc. still spends on sales and medical support even when partners handle commercialization; these costs cover medical affairs, brand support, and field coordination for approved assets. In 2025, the company reported total operating expenses of $226.4 million, and these support costs help keep YUPELRI and Vibativ visible in the market.

• Medical affairs keep HCP support active
• Brand work protects asset awareness
• Partnered drugs still need coordination

Theravance Biopharma, Inc. keeps paying for regulatory filings, pharmacovigilance, quality systems, and patent upkeep because these costs protect approvals and exclusivity. In specialty biopharma, they are not optional; they are part of staying on market and defending value.

• Regulatory and quality spend is ongoing.
• Patent maintenance protects exclusivity.
• Pharmacovigilance supports post-approval compliance.

Theravance Biopharma, Inc. uses milestone payments as contract-based cash inflows when partnered programs hit clinical or regulatory steps, such as Phase 2/3 progress or approval. In 2025, milestone and other collaboration revenue was a small but meaningful part of total revenue, helping offset the company’s heavy R&D spend and supporting non-dilutive funding.

• Triggered by development or approval events

• Paid only when partners succeed

• Reduces funding pressure on R&D

Future approved-product sales could become a direct or partnered revenue line if Theravance Biopharma, Inc.'s pipeline wins approval. Izencitinib, ampreloxetine, and nezulcitinib are the main long-range growth bets, and today they are still precommercial, so this stream has no approved-product sales yet.

• Approval would unlock direct sales or licensing income
• Izencitinib, ampreloxetine, nezulcitinib drive upside
• Main long-term growth engine, but still clinical-stage